STING1 and neoplasm: Upon exposure to ultra-high dose-rate (FLASH) irradiation, MSA-2 activated the STING pathway, elevating type I interferon levels, promoting dendritic cell (DC) maturation, and reprogramming the immunosuppressive tumor microenvironment (TME), thereby mitigating radioresistance and optimizing FLASH radiotherapy outcomes [133].